IFNA17 and hepatocellular carcinoma: About 75% of patients achieve no therapeutic benefit from the present combination therapy with pegylated interferon α (PEG-IFN-α) and ribavirin mainly depending upon HCV genotype, whereas in 40-60% patients chronic infection is mainly associated with liver cirrhosis and steatosis leading to hepatocellular carcinoma (HCC) [3-5].